Aquestive receives FDA CRL for Anaphylm allergic reaction treatment

​Aquestive has received a CRL from the FDA regarding its NDA for Anaphylm, which aims to treat type I allergic reactions in patients weighing 30kg or more.

The post Aquestive receives FDA CRL for Anaphylm allergic reaction treatment appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.